These data indicate that immunochemotherapy of CBDCA combined with anti-PD-1 antibodies increases the expression of CCL4 in the secondary tumor, which subsequently to recruit CD103+ DC and CD8+ T cells to mediate the tumor-killing effect in TNBC models. Here, CCL4 is linked to neoplasm.